Preliminary Results for the Year Ended 31 December 2023
April 19, 2024 08:00 ET
|
Biodexa Pharmaceuticals PLC
19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa...
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 08, 2024 07:30 ET
|
XOMA Corporation
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related...
Vehicle-to-Grid Technology Market projected to reach USD 12.3 Billion by 2030, growing at a CAGR of 21.5% during the forecast period of 2023-2030 - says MarketDigits in its latest study
February 01, 2024 10:15 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 01, 2024 (GLOBE NEWSWIRE) -- According to a research report "Vehicle-to-Grid Technology Market”, By Component (Smart Meters, Electric Vehicle Supply Equipment (EVSE), Home Energy...
Blood Brain Barrier Market projected to reach USD 5.22 Billion by 2030, growing at a CAGR of 21.5% during the forecast period of 2023-2030 - says MarketDigits in its latest study
January 17, 2024 10:00 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Jan. 17, 2024 (GLOBE NEWSWIRE) -- According to a research report "Blood Brain Barrier Market”, By Application (Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, Multiple Sclerosis,...
Interim results for the six months ended 30 June 2023
September 29, 2023 16:30 ET
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
August 08, 2023 07:30 ET
|
XOMA Corporation
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from...
Bioasis Provides Corporate Update and Announces Suspension of Operations
June 20, 2023 17:25 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Preliminary Results for the Year Ended 31 December 2022
April 28, 2023 16:30 ET
|
Biodexa Pharmaceuticals PLC
28 April 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2022 Biodexa Pharmaceuticals...
Bioasis Provides Update on Business Operations
March 23, 2023 17:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Announces AGM Results and Provides Update on Financial Position
February 03, 2023 17:39 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...